Skip to main content
Top
Published in: Journal of Cancer Education 2/2020

01-04-2020 | Ovarian Cancer

Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation

Authors: Terri Jabaley, Meghan L. Underhill-Blazey, Donna L. Berry

Published in: Journal of Cancer Education | Issue 2/2020

Login to get access

Abstract

For women who are unaffected carriers of a pathogenic BRCA mutation, cancer risk management requires ongoing education, counseling, and support from an interdisciplinary team of medical specialists, genetic counselors, and nurses specializing in genomics. The purpose of this study was to develop and pilot test an educational, patient-focused decision aid to facilitate shared decision making. A steering committee developed the prototype aid after an extensive review of the literature. The aid was designed at the ninth-grade reading level, to be consistent with internationally accepted clinical guidelines and inclusive of all risk management options and psychosocial issues important to cancer risk management decision making. The aid was tested with 23 participants: eight experts and 15 end users. Eleven survey items were asked related to organization, clarity, usefulness, comprehensiveness, ease of understanding, and relevance to the cancer risk management decision-making process. Mean scores were 3 or higher on Likert scales of 1–4 (high) for each of the 11 items. Two open-ended questions elicited general comments and suggestions for additions, deletions, or revisions to the decision aid. The steering committee made final revisions to the aid based on participant feedback and committee consensus.
Literature
4.
go back to reference Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, Weitzel JN (2011) Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns 20(3):294–307CrossRef Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, Weitzel JN (2011) Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns 20(3):294–307CrossRef
6.
go back to reference Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME (2009) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9):593–597CrossRef Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME (2009) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9):593–597CrossRef
7.
go back to reference Heijer M, Seynaeve C, Vanheusden K, Timman R, Duivenvoorden HJ, Tilanus-Linthorst M, Menke-Pluijmers MBE, Tibben A (2013) Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3):598–604. https://doi.org/10.1002/pon.3039 CrossRef Heijer M, Seynaeve C, Vanheusden K, Timman R, Duivenvoorden HJ, Tilanus-Linthorst M, Menke-Pluijmers MBE, Tibben A (2013) Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3):598–604. https://​doi.​org/​10.​1002/​pon.​3039 CrossRef
11.
go back to reference Kaufman EM, Peshkin BN, Lawrence WF, Shelby R, Isaacs C, Brown K, Rispoli J, O'neill S, Hurley K, DeMarco T (2003) Development of an interactive decision aid for female BRCA1/BRCA2 carriers. J Genet Couns 12(2):109–129CrossRef Kaufman EM, Peshkin BN, Lawrence WF, Shelby R, Isaacs C, Brown K, Rispoli J, O'neill S, Hurley K, DeMarco T (2003) Development of an interactive decision aid for female BRCA1/BRCA2 carriers. J Genet Couns 12(2):109–129CrossRef
12.
go back to reference Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112. CrossRefPubMed Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://​doi.​org/​10.​1001/​jama.​2017.​7112.​ CrossRefPubMed
14.
go back to reference Llort G, Chirivella I, Morales R, Serrano R, Beatriz Sanchez A, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B (2015) SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol 17(12):956–961CrossRef Llort G, Chirivella I, Morales R, Serrano R, Beatriz Sanchez A, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B (2015) SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol 17(12):956–961CrossRef
15.
18.
go back to reference Petrucelli, Nancie, Mary B Daly, and Tuya Pal. 2016. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer. Petrucelli, Nancie, Mary B Daly, and Tuya Pal. 2016. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.
20.
go back to reference Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW (2013) Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial Cancer 12(1):65–73CrossRef Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW (2013) Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial Cancer 12(1):65–73CrossRef
24.
go back to reference Tiller K, Meiser B, Reeson E, Tucker M, Andrews L, Gaff C, Kirk J, Phillips KA, Friedlander M (2003) A decision aid for women at increased risk for ovarian cancer. Int J Gynecol Cancer 13(1):15–22CrossRef Tiller K, Meiser B, Reeson E, Tucker M, Andrews L, Gaff C, Kirk J, Phillips KA, Friedlander M (2003) A decision aid for women at increased risk for ovarian cancer. Int J Gynecol Cancer 13(1):15–22CrossRef
Metadata
Title
Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation
Authors
Terri Jabaley
Meghan L. Underhill-Blazey
Donna L. Berry
Publication date
01-04-2020
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 2/2020
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-019-1470-9

Other articles of this Issue 2/2020

Journal of Cancer Education 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine